Bruce Kennedy ~ WeedWorthy.com ~

A group of U.S. lawmakers is calling on the U.S. Drug Enforcement Administration (DEA) of remove federal barriers on medical marijuana research and to ease new medical research on cannabis and its derivatives.

 The letter, published Thursday and addressed to Chuck Rosenberg, the DEA’s Acting Administrator, was signed by Senator Kirsten Gillibrand (D-NY), along with Senators Cory A. Booker (D-NJ), Jeffrey A. Merkley (D- OR), Barbara Boxer (D-CA), and U.S. Representatives Earl Blumenauer (D-OR), Dana Rohrabacher (R-CA), Jared Polis (D-CO) and Ted Lieu (D-CA).

It also requested a meeting with Administrator Rosenberg if he does not take action on medical marijuana.

The Senators and Representatives noted that more than half of U.S. states have passed laws legalizing medical marijuana, while 42 states allow the medicinal use of cannabis-derived substances.

“Nevertheless, federal policies continue to hinder medical researchers’ ability to study the benefits of cannabis, particularly as a therapy for conditions which are resistant to other forms of treatment,” their letter continued.

It also cited information from the U.S. Department of Health and Human Services (HHS), which has reportedly determined “that medication naturally derived from the cannabis plant has a medical use.”

Just last week, several of the senators cited in the Thursday letter were signatories on another letter to the DEA; requesting an update on the DEA’s decision about whether to adjust marijuana's classification as a Schedule I drug under the Controlled Substances Act (CSA).

Drugs with a Schedule 1 classification are currently considered as having "no accepted medical use and a high potential for abuse."

According to that earlier letter, the DEA previously indicated that a new scheduling determination would occur in the "first half of 2016."

“While we appreciate the DEA’s willingness to maintain an open dialogue with our offices, the senators continued in their June 23 letter, "we are concerned that ‘the first half of 2016’ is coming to a close and no rescheduling announcement has been made.”

The senators added they believe the rescheduling of cannabis and the resolution of regulatory barriers to research on marijuana “is a time-sensitive matter that requires immediate action,” asking for a briefing on the DEA’s decision regarding rescheduling “no later than July 5.”

Recent News Articles

Thursday November 07

High flyers: legal cannabis creates grey area for US airports - Cannabis News

in Travel

by Bruce Kennedy - Editor in Chief

As US states continue to legalise cannabis for medical and recreational use, an awkward tangle…

2018 hits

Thursday November 07

Too much weed: Canadian cannabis producers are sitting on a mountain of inventory - Cannabis…

in Finance

by Bruce Kennedy - Editor in Chief

'I suspect it’ll be a race to the bottom with price because everyone now has…

1984 hits

Thursday November 07

Michigan State Police Don't Know What to do With All These Marijuana Smells - Cannabis…

in Law & Crime

by Bruce Kennedy - Editor in Chief

Recreational marijuana became legal in Michigan on December 6, 2018. However, law enforcement is still…

1970 hits

Friday November 08

California mom challenging district over child's use of cannabis oil at school - Cannabis News

in Law & Crime

by Bruce Kennedy - Editor in Chief

"It is OK for him to have valium in class... but God forbid we have…

1955 hits

Friday November 08

Belgian Jewish baker launches mass-produced cannabis bread - Cannabis News

in Culture & Arts

by Bruce Kennedy - Editor in Chief

When it hits the shelves later this month, the organic Cannabread will have the taste…

1893 hits